 AIkido Pharma Inc. Nasdaq: AIKI AIkido or the Company today announced that it will provide funding for a 30-day survival study in mice in collaboration with University of Kentucky related to the anticancer drug designated G4-1, a novel proteasome inhibitor. In exchange, Aikido has been granted an exclusive option to license the drug Option pending the results of the study. 